Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.
The information provided here is drawn from ClinicalTrials.gov. If you do not find a satisfactory expanded access program here, please search in our COVID Company Directory. Some companies consider expanded access requests for single patients, even if they do not show an active expanded access listing in this database. Please contact the company directly to explore the possibility of expanded access.
Emergency INDs
To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.
Search Tips
To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.
Displaying 150 of 370Medical University of South Carolina
The purpose of this study is to evaluate how useful vitamin D supplementation is inreducing the severity of COVID-19 symptoms and the body's inflammatory andinfection-fighting response to COVID-19. Individuals ≥50 years of age and older who aretested for COVID-19 and negative will be randomized (like flipping a coin) to eitherdaily high dose vitamin D supplementation (6000 IU vitamin D3/day) vs. standard of care.Those individuals ≥50 years of age or older who test positive for COVID-19 at baselinewill be randomized to bolus vitamin D (20,000 IU/day for 3 days) followed by high dose(6000 IU vitamin D/day) vs. standard of care for 12 months. All participants will receivea multivitamin containing vitamin D.
Humanetics Corporation
This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate thesafety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lungfunction in patients that were hospitalized for severe COVID-19-related illness andcontinue to experience post-acute respiratory complications associated with Long-COVIDafter discharge. Patients will be randomized 1:1 to receive BIO 300 or placebo.
University Health Network, Toronto
Recent studies have shown that some individuals may be asymptomatic but continue to shedthe COVID-19 virus. These individuals may represent a population that can unknowinglytransmit the virus. Healthcare workers (HCW) may acquire COVID-19 from the community orfrom possibly infected patients. It is important to gather data with respect to this tofurther understand the prevalence of asymptomatic carriage in individuals who work inresearch facilities, offices and clinical areas of hospitals and researchfacilities/institutes since this has important implications for infection control, aswell as staff and patient safety. The purpose of this study is to test whether aproportion of these individuals may be asymptomatic shedders of the COVID-19 virus.
Brigham and Women's Hospital
Ultomiris (Ravulizumab), is a monoclonal antibody that specifically targets terminalcomplement products and is proposed for the treatment of COVID-19 inducedmicrovasculature injury and endothelial damage leading to thrombotic microangiopathy(TMA) causing acute kidney injury (AKI). Ravulizumab is to be used for participants witha confirmed diagnosis of COVID-19 who clinically or diagnostically present withdeteriorating renal function. Ravulizumab causes immediate and sustained inhibition ofthe terminal complement cascade. The use of ravulizumab could ameliorate COVID-19 inducedkidney injury due to TMA, shorten hospital stay, and improve the overall survival.
University of Kansas Medical Center
Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.
Lahore General Hospital
This study will define the kinetics of IgG responses to both N and S proteins in thesubjects who suffered from COVID 19 and then had recovered and those who were previouslyundiagnosed but were seropositive. These subjects will be followed for four months toevaluate the levels of antibodies in these people.
Imperial College London
The proposed study is designed to investigate if and how pregnant women infected withCoronavirus Disease-19 (COVID-19) infection go on to develop long-term immunity. InDecember 2019, a group of people in Wuhan, China presented with symptoms of a pneumoniaof an unknown cause that led to the discovery of a new coronavirus called COVID-19.COVID-19 has caused a global pandemic with 7,140,000 confirmed cases and 418,000 deathsas of 13th June 2020. In the United Kingdom (UK), there have been 294,000 cases and41,662 deaths as of 13th June 2020. In humans, this infection primarily involves theupper part of the lungs, but it can also affect other organs. It causes mild symptoms inthe majority of people affected but some people can have severe infections, with someeven requiring critical care in hospital. During Severe acute respiratory syndrome(SARS), a previous coronavirus epidemic, pregnant women were disproportionately affectedwith severe illness. Understanding how the immune system responds long-term to thisinfection may hold the key to developing better vaccines and efficient treatment plans.Specialised immunity develops when individuals are infected by this and other viruses.The investigators of this study propose that, in pregnancy, this specialised immunity maynot behave effectively. This may affect their ability to develop long lasting immunityand make them more vulnerable to re-infection. In this study, the investigators aim torecruit patients across 6 groups including COVID-19 newly infected pregnant women, andpeople with differing illness severity, mild to moderate, severe/critical, no infection(controls), as well as pregnant women with influenza and those receiving influenzavaccine. The study team will compare COVID-19 in pregnancy with non-pregnant infected andwith influenza infected and vaccinated pregnant women. The study team will consentpatients in all of these groups to provide a series of blood samples at different timepoints in a 12-month period.
Assiut University
To evaluate the spectrum of comorbidities and complications and its impact on theclinical outcome in hospitalized patients with coronavirus disease 2019 (COVID-19).
Centre Hospitalier Universitaire, Amiens
The data obtained from Covid-19 infections seem to suggest that the immunogenesis ofCovid-19 could in some cases be the result of immune dysregulation. On the other hand,endocrine damage is possible at the tile of Covid-19 infection (mainly thyroid,adrenal,and hypothalamus). These disorders are autoimmune or linked to degeneration.The main objective is to assess the thyroid function (thyrotropic axis) as well as thecorticotropic adrenal function of patients who have had Copvid-19 pneumonia. Thesecondary objectives is to describe the pathophysiological mechanisms of pulmonary andvasculothrombotic involvement of Covid-19
Centre Hospitalier Universitaire, Amiens
This study aims to determine how long COVID-19 neutralizing antibodies can be detected inan elderly institutionalized population presenting fragility factors.This study also aims to stratify seroconversion by immunological profiles of the elderlypatients residing in the EHPAD. This stratification requires the measurement ofimmunological marker levels already described in immunosenescence and also involved inthe development of certain chronic infectious diseases more common in the elderlypopulation. This analysis will enable the investigators to describe an immunological,clinical and biological profile representing a patient who has developed an immunityagainst COVID 19. It will also help the investigators to understand the differentmechanisms leading to a reduced immune response after a potential administration of avaccine. Finally, it will help describe the immune profiles of elderly residents whopresented with non-severe forms of COVID-19.